-
Mashup Score: 16Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy - 27 day(s) ago
Key Points. Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamabPati
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Yuval Noah Harari argues that AI has hacked the operating system of human civilisation - 29 day(s) ago
Storytelling computers will change the course of human history, says the historian and philosopher
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Daniel Kahneman was a master of teasing questions - 29 day(s) ago
How a psychologist transformed economics
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis - 29 day(s) ago
Blood Cancer Journal – Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma - 29 day(s) ago
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for CAR-T and bispecific antibody therapy, and/or patients progressing on anti-CD38 treatment where CAR-T and bispecifics might be kept in reserve. Wider use of the drug can be challenged by its distinct ocular side effect profile, including corneal microcysts and keratopathy. While dose reduction has been the most effective way to reduce these toxicities, the underlying mechanism of this BCMA off-target effect remains to be characterized. In this study, we provide the first evidence for soluble BCMA (sBCMA) in lacrimal fluid and report on its correlation with tumor burden in myeloma patients. We confirm that corneal cells do not express BCMA, and show that sBCMA-belantamab complexes may rather be internalized by corneal epithelial cells through receptor-ligand inde
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy - 29 day(s) ago
Key Points. Despite the high initial rates of response to anti-BCMA CAR-T cell therapy in myeloma, those responses are frequently short-lived.Exhausted CD4
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Humans are imperfect, inconsistent decision-makers - 1 month(s) ago
In their new book, Daniel Kahneman, Olivier Sibony and Cass Sunstein offer strategies for improvement
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Two Brains Running (Published 2011) - 1 month(s) ago
In the conflict between intuitive and rational decision-making, which side wins?
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Not so smart now - 1 month(s) ago
The father of behavioural economics considers the feeble human brain
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Daniel Kahneman, Who Plumbed the Psychology of Economics, Dies at 90 - 1 month(s) ago
He helped pioneer a branch of the field that exposed hard-wired mental biases in people’s economic behavior. The work led to a Nobel.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamab #mmsm #bmtsm @szusmani @BloodAdvances https://t.co/wNHrF0QkkZ